文献速递生殖医学妇科

女性癌症幸存者生育力:系统综述与荟萃分析

Fertility in female cancer survivors: a systematic review and meta-analysis.
PubMed 文献 · Reprod Biomed Online · 2020-02-22

该系统综述与荟萃分析检索PubMed、MEDLINE、Embase和Scopus(建库至2019年7月17日),纳入18项队列、病例对照和横断面研究,评估不同类型癌症女性幸存者的分娩机会。结果显示骨癌、乳腺癌、脑癌和肾癌幸存者分娩机会显著降低,而非霍奇金淋巴瘤、黑色素瘤和甲状腺癌幸存者的生育机会未受影响。

要点

  • 骨癌、乳腺癌、脑癌和肾癌幸存者分娩机会显著降低。
  • 非霍奇金淋巴瘤、黑色素瘤和甲状腺癌幸存者生育机会未受影响。
  • 咨询时应按癌症类型分层评估生育风险。

核心结论

  • 有骨癌、乳腺癌、脑癌或肾癌病史的女性分娩机会降低。
  • 甲状腺癌、黑色素瘤和非霍奇金淋巴瘤幸存者的生育机会可获 reassurance( reassurance 意为可放心)。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、MEDLINE、Embase和Scopus自建库至2019年7月17日。
  • 纳入18项队列、病例对照和横断面研究,评估不同癌症类型女性幸存者的生殖机会。
  • 采用随机效应模型合并分娩风险比、相对危险度、率比和比值比,并估计95%CI。

主要发现

  • 骨癌:HR 0.86(95%CI 0.77–0.97;I2=0%;P=0.02,两项研究);RaR 0.76(95%CI 0.61–0.95;I2=69%;P=0.01,两项研究)。
  • 乳腺癌:HR 0.74(95%CI 0.61–0.90,一项研究);RaR 0.51(95%CI 0.47–0.57;I2=0%;P<0.00001,两项研究)。
  • 脑癌:HR 0.61(95%CI 0.51–0.72;I2=14%;P<0.00001,三项研究);RR 0.62(95%CI 0.42–0.91,一项研究);RaR 0.44(95%CI 0.33–0.60;I2=95%;P<0.00001,四项研究);OR 0.49(95%CI 0.40–0.60,一项研究)。
  • 肾癌:RR 0.66(95%CI 0.43–0.98,一项研究);RaR 0.69(95%CI 0.61–0.78,一项研究)。
  • 非霍奇金淋巴瘤、黑色素瘤和甲状腺癌幸存者的生殖机会未受影响。

关键数值与推荐

  • 骨癌幸存者分娩机会降低:HR 0.86(95%CI 0.77–0.97)、RaR 0.76(95%CI 0.61–0.95)。
  • 乳腺癌幸存者分娩机会降低:HR 0.74(95%CI 0.61–0.90)、RaR 0.51(95%CI 0.47–0.57)。
  • 脑癌幸存者分娩机会降低:HR 0.61(95%CI 0.51–0.72)、RaR 0.44(95%CI 0.33–0.60)、OR 0.49(95%CI 0.40–0.60)。
  • 肾癌幸存者分娩机会降低:RR 0.66(95%CI 0.43–0.98)、RaR 0.69(95%CI 0.61–0.78)。

临床怎么用

  • 对骨癌、乳腺癌、脑癌和肾癌女性幸存者应提前进行生育力保护和生育咨询。
  • 对甲状腺癌、黑色素瘤和非霍奇金淋巴瘤幸存者可告知其生育机会未受显著影响。
  • 临床决策应结合癌症类型分层评估分娩机会。

局限性

  • 部分癌症类型的合并结果仅基于一项或两项研究。
  • 部分合并结果异质性较高(如脑癌RaR的I2=95%、骨癌RaR的I2=69%)。
  • 检索截止至2019年7月17日,未纳入此后发表的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on the effects of cancer treatments on fertility are conflicting. The aim of the present systematic review and meta-analysis was to determine the chances of childbirth in women survivors of different types of cancer. PubMed, MEDLINE, Embase and Scopus were searched from database inception to 17 July 2019 for published cohort, case-control and cross-sectional studies that investigated the reproductive chances in women survivors of different cancer types. Random-effects models were used to pool childbirth hazard ratios, relative risks, rate ratios and odds ratios, and 95% confidence intervals were estimated; 18 eligible studies were identified. Childbirth chances were significantly reduced in women with a history of bone cancer (HR 0.86, 95% CI 0.77 to 0.97; I2 = 0%; P = 0.02 (two studies); RaR 0.76, 95% CI 0.61 to 0.95; I2 = 69%; P = 0.01 (two studies); breast cancer (HR 0.74, 95% CI 0.61 to 0.90 (one study); RaR 0.51, 95% CI 0.47 to 0.57; I2 = 0%; P < 0.00001 (two studies); brain cancer (HR 0.61, 95% CI 0.51 to 0.72; I2 = 14%; P < 0.00001 (three studies); RR 0.62, 95% CI 0.42 to 0.91 (one study); RaR 0.44, 95% CI 0.33 to 0.60; I2 = 95%; P < 0.00001 (four studies); OR 0.49, 95% CI 0.40 to 0.60 (one study); and kidney cancer (RR 0.66, 95% CI 0.43 to 0.98 (one study); RaR 0.69, 95% CI 0.61 to 0.78 (one study). Reproductive chances in women survivors of non-Hodgkin's lymphoma, melanoma and thyroid cancer were unaffected. Women with a history of bone, breast, brain or kidney cancer have reduced chances of childbirth. Thyroid cancer, melanoma and non-Hodgkin's lymphoma survivors can be reassured.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Busnelli A, Vitagliano A, Mensi L, et al. Fertility in female cancer survivors: a systematic review and meta-analysis. Reprod Biomed Online. 2020. PMID: 32456969. doi:10.1016/j.rbmo.2020.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。